

Resource Summary Report

Generated by [RRID](#) on Aug 12, 2026

European Molecular Quality Network

RRID:SCR_008494

Type: Tool

Proper Citation

European Molecular Quality Network (RRID:SCR_008494)

Resource Information

URL: <http://www.emqn.org>

Proper Citation: European Molecular Quality Network (RRID:SCR_008494)

Description: Welcome to the EMQN website. EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines. The European Molecular Genetics Quality Network (EMQN) started in October 1998 after a successful pilot trial. From January 1999 to March 2002, the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515). From April 2002, the network is supported by subscriptions from its users. External Quality Assessment (EQA): There are 26 EQA schemes being offered in 2010. To participate you must be a registered member of the network. For more information on EQA schemes, click the link here. Best Practice: EMQN is actively promoting "best practice" meetings on individual diseases. To assist in this process, EMQN will be organising best practice meetings. To participate you must be a registered member of the network. Following the meeting, draft best practice guidelines are produced and published on this and other related websites, for example, the web site of the UK Clinical Molecular Genetics Society (CMGS). To find out more about best practice click here. Administration: The EMQN is based at the National Genetics Reference Laboratory (Manchester), St Mary's Hospital, Manchester, The United Kingdom. The Network is co-ordinated and administered by Dr's Rob Elles and Simon Patton. A management group is responsible for the activities and direction of the network. National partners in different countries help to disseminate information about the network. Quality Policy The EMQN provides a comprehensive range of quality assurance programs for molecular genetics to laboratories and industry worldwide. The European Molecular Genetics Quality Network (EMQN) is committed to helping ensure diagnostic molecular genetic laboratory test results are accurate, reliable and comparable wherever they are produced. The EMQN will provide a high quality and timely service which takes into account the needs and requirements of its users. Objectives To help to raise and maintain the standards of diagnostic clinical molecular genetic testing. To undertake and promote educational activities. To be a leading authority

in quality assurance . To design and provide the best possible materials and data management. To design and provide quality reports that are timely and valid. To provide professional support and consultation. To develop new programs as required. To participate in peer review. To strive for continual improvement of the quality system. Sponsor. the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515

Synonyms: EMQN

Resource Type: data or information resource, portal, organization portal

Resource Name: European Molecular Quality Network

Resource ID: SCR_008494

Alternate IDs: nif-0000-30493

Record Creation Time: 20220129T080247+0000

Record Last Update: 20260812T044142+0000

Ratings and Alerts

No rating or validation information has been found for European Molecular Quality Network.

No alerts have been found for European Molecular Quality Network.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lundie B, et al. (2026) Piloting an Interpretive External Quality Assurance Model for Genomic Testing for Childhood Syndromes and Intellectual Disability. The Journal of molecular diagnostics : JMD, 28(3), 227.

Chan HJ, et al. (2026) IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling. Analytical chemistry, 98(7), 5227.

Rim JH, et al. (2025) Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine. Annals of laboratory medicine, 45(2), 121.

Werner R, et al. (2025) Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratory. *Journal of clinical pathology*, 78(11), 783.

Fairley JA, et al. (2024) Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey. *Virchows Archiv : an international journal of pathology*, 485(4), 717.

McDevitt T, et al. (2024) EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. *European journal of human genetics : EJHG*, 32(5), 479.

Murphy R, et al. (2023) The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion. *Communications medicine*, 3(1), 136.

Wijekoon N, et al. (2023) Duchenne Muscular Dystrophy from Brain to Muscle: The Role of Brain Dystrophin Isoforms in Motor Functions. *Journal of clinical medicine*, 12(17).

Hayesmoore JB, et al. (2023) EMQN: Recommendations for genetic testing in inherited cardiomyopathies and arrhythmias. *European journal of human genetics : EJHG*, 31(9), 1003.

Eichstaedt CA, et al. (2023) Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. *The European respiratory journal*, 61(2).

Murphy R, et al. (2023) A Systematic Review of the use of Precision Diagnostics in Monogenic Diabetes. *medRxiv : the preprint server for health sciences*.

Nader A, et al. (2022) Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. *Clinical and translational science*, 15(5), 1269.

Stark Z, et al. (2021) Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution. *American journal of human genetics*, 108(9), 1551.

Akolkar D, et al. (2021) Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors. *PloS one*, 16(2), e0246048.

Hottentot QP, et al. (2021) Breakpoint characterization of a rare alpha0 -thalassemia deletion using targeted locus amplification on genomic DNA. *International journal of laboratory hematology*, 43(6), 1628.

Ozi??b??o D, et al. (2020) Cochlear Implantation Outcome in Children with DFNB1 locus Pathogenic Variants. *Journal of clinical medicine*, 9(1).

Gutowska-Ding MW, et al. (2020) One byte at a time: evidencing the quality of clinical service next-generation sequencing for germline and somatic variants. *European journal of human genetics : EJHG*, 28(2), 202.

Nero C, et al. (2020) Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study). Scientific reports, 10(1), 16511.

Baumgartner-Parzer S, et al. (2020) EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. European journal of human genetics : EJHG, 28(10), 1341.

Delcourt T, et al. (2020) NGS for (Hemato-) Oncology in Belgium: Evaluation of Laboratory Performance and Feasibility of a National External Quality Assessment Program. Cancers, 12(11).